Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside

Alimentary Pharmacology and Therapeutics

Volumn 50, Issue 4, 2019, Pages 397-406

  Detlie, Trond Espen ^a,b   Lindstrøm, Jonas Christoffer ^a,b   Jahnsen, Marte Eide ^a   Finnes, Elisabeth ^c   Zoller, Heinz ^d   Moum, Bjørn ^b,c   Jahnsen, Jørgen ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; IRON ISOMALTOSIDE; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION; IRON ISOMALTOSE; MALTOSE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; HYPOPHOSPHATEMIA; INCIDENCE; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; CLINICAL TRIAL; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NORWAY; QUALITY OF LIFE;

ADMINISTRATION, INTRAVENOUS; ADULT; ANEMIA, IRON-DEFICIENCY; DISACCHARIDES; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MALTOSE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS;

EID: 85069935425     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.15386     Document Type: Article

References (39)

1. Dignass AU, Gasche C, Bettenworth D, et al.; European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
2. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:513-519.
3. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599-610.
4. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
5. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460-1467.
6. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266-275.
7. Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE. 2016;11:e0167146
8. Bartko J, Roschger P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. 2018;33:534-539.
9. Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017;152:e5-e6.
10. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018;2018.
11. Urbina T, Belkhir R, Rossi G, et al. Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit. J Bone Miner Res. 2018;33:540-542.
12. Reyes M, Diamond T. Hypophosphataemic rickets due to parenteral ferrous carboxymaltose in a young man with Crohn disease and iron deficiency: a case report and review of literature. J Clin Case Rep. 2017;7:931.
13. Phan T, Liebman SEA case of hypophosphatemia due to ferric carboxymaltose induced renal phosphate wasting. Abstract presented at the American Nephrology Society Kidney Week; 31 October–5 November. New Orleans, LA, USA; 2017.
14. Auerbach M, Thomsen LL. A single infusion of iron isomaltoside 1000 allows a more rapid hemoglobin increment than multiple doses of iron sucrose with a similar safety profile in patients with iron deficiency anemia. Abstract presented at the American Society of Hematology Annual Meeting & Exposition; December 1–4.San Diego, CA, USA; 2018.
15. ®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577-1589.
16. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial. Pharmacotherapy. 2016;36:402-414.
17. Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286-291.
18. ®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53-64.
19. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719-2728.
20. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793-1803.
21. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3:e124486.
22. Goretti Penido M, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012;27:2039-2048.
23. Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14:R147.
24. Grabowski SR, Tortora GJ. Principles of anatomy and physiology. 9th ed. New York, NY: Wiley; 2000.
25. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49-53.
26. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine. 2000;79:1-8.
27. Burckhardt P. Eisen-induzierte osteomalazie. Osteologie. 2018;27:20-23.
28. Bart G, Glemarec J, Lerhun M, et al.A rusty man…or how iron can be responsible for bone pain. Symptomatic hypophosphataemic osteomalacia after iron carboxymaltose treatment. The Rheumatologist’s Newsletter. No. 428; 2017.
29. Etchenique MP, Diehl M, Kitaigrodsky AV, et al. Hypophosphatemia and osteomalacia induced by intravenous iron. Bone. 2016;89:65.
30. Moore K, Kildahl-Andersen O, Kildahl-Andersen R, Tjønnfjord GE. Uncommon adverse effect of a common medication. Tidsskr Nor Legeforen. 2013;2:165.
31. Poursac N. Hypophosphatemia and elevated FGF23: it is not always an oncogenic phosphate diabetes patient. Rhumatoos. 2015;12:61-64.
32. Sangrós Sahún MJ, Goñi Gironés E, Camarero Salazar A, Estébanez C, Lozano Martínez ME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016;35:391-393.
33. Tournis S, Michopoulos S, Makris K, Terpos E. Re: hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. 2018;33:543-545.
34. National Health Service. Guideline for the Treatment of Hypophosphatemia in Adults. March 2016. https://www.nuh.nhs.uk/download.cfm?doc=docm93jijm4n3161.pdf&ver=5196. Accessed March 4, 2019.
35. Frigstad SO, Haaber A, Bajor A, et al. The NIMO Scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract. 2017;2017:4585164.
36. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-1602.
37. McDonagh T, Damy T, Doehner W, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20:1664-1672.
38. Aapro M, Beguin Y, Bokemeyer C, et al. ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl. 4):iv96-iv110.
39. Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72:233-247.